Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic... Read More

Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, " Metal Nanoparticles and Methods of Making Same ". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the... Read More

Halifax, Nova Scotia--(Newsfile Corp. - October 9, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will... Read More

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company " or " Sona ") is pleased to announce that it has closed its non-brokered private placement that was announced on September 5, 2024 with the issuance of 6,575,000 common shares (each, a " Share ") at $0.25 per share (the " Financing ") for gross proceeds of $1,643,750. One Insider of Sona subscribed for... Read More

Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company " or " Sona ") is pleased to announce that it has closed its non-brokered private placement that was announced on July 31, 2024 with the issuance of 6,000,000 common shares (each, a " Share ") at $0.25 per share (the " Financing "). As previously disclosed, Sona intends to use the net proceeds of the... Read More

Halifax, Nova Scotia--(Newsfile Corp. - July 31, 2024) - Sona Nanotech Inc. ( CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing (the " Financing ") of up to 6,000,000 common shares of Sona (each, a " Share ") at a price of $0.25 per Share (the " Offering Price "). Insiders and certain other existing shareholders of Sona... Read More

Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors... Read More

Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted... Read More

Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a... Read More

Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These... Read More

Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data... Read More